Mankind ipo grey market price

Mankind Pharma IPO: The initial public offering (IPO) of Mankind Pharma Ltd is going to hit stock market today. As epr the information available on BSE website, Mankind Pharma share price is going to list on both NSE and BSE on 9th May 2023 i.e. today. Thus, ₹120 per equity share in grey market today while stock market experts are also expecting positiver debut of Mankind Pharma shares. They said that an allottee may have a listing premium to the tune of 10-12 per cent and Mankind Pharma IPO listing price could be around ₹1300 apiece, provided bull trend continues on Dalal Street today. Mankind Pharma share price debut: What experts feel? Speaking on Mankind Pharma share price debut, Prashanth Tapse, Senior Vice President at Mehta Equities said, "Expecting a decent listing gains of around 7-10 per cent on the issue price considering healthy market mood and a strong subscription response from the investors, led by the institutions while the offer also witnessed muted response from the retailers due to concern on 100 per cent OFS." On expected Mankind Pharma IPO listing price, Ravi Singhal, CEO at GCL Broking said, "Much will depend upon the kind of opening ₹1,300 apiece levels whereas in bear case, we may see Mankind Pharma ₹1,100 apiece levels." Mankind Pharma IPO GMP today As mentioned above, market observers have informed that Mankind Pharma IPO GMP (grey market premium) today is ₹120 per equity share, which is ₹17 higher from its yesterday's GMP of ₹103. Observers went ...

Mankind Pharma IPO: The initial public offering ((IPO) of Mankind Pharma Ltd opened for subscription on 25th April 2023 and it will remain open for bidding till 27th April 2023. This means, today is the last day to apply for the public issue worth ₹4,326.36 crore. As per the Mankind Pharma IPO subscription status, by 11:09 AM on day three of bidding, the public issue got fully6 subscribed. According to market observers, shares of Mankind Pharma is available at a premium of ₹70 in grey market today. 2] Mankind Pharma IPO subscription status: By 03:05 AM on day 3 of bidding, the public issue has been subscribed 10.45 times whereas its retail portion has been subscribed 0.69 times. The public offer has been fully subscribed in NII and QIB category. In NII category, the IPO has been subscribed 3.18 times whereas in QIB segment, it has been subscribed 34.18 times of its original offer. 3] Mankind Pharma IPO date: The public issue opened for subscription on 25th April 2023 and it will remain open for bidding till 27th April 2023. 4] Mankind Pharma IPO price band: Manforce and Prega News maker company has fixed price band of its public offer at ₹1026 to ₹1080 apiece. 5] Mankind Pharma IPO lot size: A bidder will be able to apply in lots and one lot of the IPO will comprise 13 shares. 6] Mankind Pharma IPO investment limit: As one lot will have 13 company shares, minimum amount required for a retail investor to apply for Mankind Pharma IPO is ₹14,040 ( ₹1080 x 13). 7] Mankind Phar...

IPO Size: Rs. 4,326 cr • Entirely offer for sale (OFS) – comprising 1/4 th by promoters (79% to 76%), 3/4 th by 2 PE investors Capital International and ChrysCapital (21% to drop to 13%) Price band: Rs. 1,026-1,080 per share M cap: Rs. 43,264 cr, implying 10% dilution IPO Date: Tue 25 th April to Thu 27 th April 2023, Listing Tue 9 th May 2023 Grey Market Premium (GMP): We are strongly against ‘ grey market premium’ as it is an unofficial figure, against SEBI guidelines. India’s Fourth Largest Pharma Company Mankind is an India focused branded generics pharmaceutical company, clocking 10% of Rs. 8,500 cr annual revenue from over-the-counter (OTC) healthcare products like contraceptives, pregnancy kits, antacids etc and 90% from higher-margin chronic and acute pharma segments, in the ratio of 1:2. With a deep reach of 15,000+ field managers and medical representatives, Mankind enjoys 4.4% market share in Rs. 1.9 lakh cr Indian Pharmaceutical Market (IPM) and 5.7% volume market share as its drugs are competitively priced. As 98% revenue is from India, Mankind is insulated from USFDA risks plaguing some of its peers. Multiple Growth Opportunities • Mankind is only the 2 nd company in the world (after Abbott) to have developed a complex synthetic hormonal API dydrogesterone in-house (marketed as Dydroboon) , revenue from which increased from Rs. 85 cr in FY21 to Rs. 205 cr in TTM Dec 22, as market grows at 35% CAGR. A new manufacturing facility for Dydroboon export is under co...

Incorporated in 1991, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations across various acute and chronic therapeutic areas and several consumer healthcare products. In India, the business is active in a number of acute and chronic therapeutic fields, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients, and respiratory. It has over 36 brands,including Manforce (Rx), Moxikind-CV, Amlokind-AT, Unwanted-Kit, Candiforce, Gudcef, Glimestar-M, Prega News, Dydroboon, Codistar, Nurokind-Gold, Nurokind Plus-RF, Nurokind-LC, Asthakind-DX, Cefakind, Monticope, Telmikind-H, Telmikind, Gudcef-CV, and Unwanted-72, among them. Mankind Pharma has one of the largest distribution networks of medical representatives in the Indian pharmaceutical market ("IPM"). Over 80% of doctors in India prescribed their formulationsand has been ranked number 4th in terms of domestic sales during the Financial Year 2022. The company has been awarded The Best of Bharat Awards 2022 by exchange4media in the year 2022, Silver Medal from National Awards for Manufacturing Competitiveness Assessment 2021 instituted by International Research Institute for Manufacturing, and Silver Award for Good Health Brand at IHW Awards 2021 in the year 2021, Best Condom Brand of the Year award at Sex Brand Awards Pharma OTC Company of the Year Award at Pharma Excellence Awards 2018, Award for Best Design in Healthcare at Healthcare...

Mankind Pharma closed its maiden public issue on a strong note, getting subscribed over 15 times. Now all eyes will be on its share allotment which will be announced next week on May 3. The pharmaceutical company has received a robust response to its initial public offering from qualified institutional investors, who have bid 49.16 times the allotted quota, while high net-worth individuals have bought shares 3.8 times the reserved portion. However, the response from retail investors remained tepid, with only 92 percent of reserved shares subscribed. As a result, the offer has received bids for 42.95 crore equity shares subscribing 15.32 times during April 25-27. The company also received a good response in the anchor round with 16 MF schemes and names like CPPIB, Abu Dhabi Investment Authority, Goldman Sachs, Fidelity, Blackrock, GIS and Nomura participating. The Rs 4,326-crore public issue was entirely an offer for sale by promoters and investors. Hence all the money will go to the selling shareholders, and the company will not receive funds from this offer. The price band for the offer was Rs 1,026-1,080 per share and the final offer price is expected to be at the upper end of the price band. Investors in the Mankind Pharma IPO can check their share allotment status either on the BSE website or the portal of the IPO registrar, by following a few easy steps. In case of IPO registrar website, a) Select IPO "Mankind Pharma Limited" b) Select and accordingly enter either "Ap...

Mankind Pharma, whose Rs 4,326.36 crore initial public offer (IPO) received a strong response from the investors during the bidding process, is likely to announce its allotment of shares on Wednesday, May 03, 2023. The IPO of India’s fourth largest pharmaceutical company received a strong response from the investors and was overall subscribed 15.32 times. The issue was open for subscription between April 25-27 in the price range of Rs 1,026-1,080 per share. The quota reserved for qualified institutional bidders was subscribed 49.16 times, while the portion for non-institutional bidders was booked 3.80 times. The allocation of retail investors was subscribed 92 per cent. Last head, Mankind Pharma was commanding a premium of Rs 90-100 in the grey market. A majority of the brokerage firms are positive on the issue and suggest investors subscribe to the issue on a long-term basis, citing the dominant market position, strong financials, defensive sector and robust growth outlook. However, some analysts have raised red flags over rich valuations and the complete OFS nature of the issue, capping room for any stellar upside. Investors, who had bid for the issue, can check the allotment status on the Bombay Stock Exchange (BSE) website: 1) Visit https://www.bseindia.com/investors/appli_check.aspx 2) Under the issue type, click Equity 3) Under the issue name, select Mankind Pharma Limited in the dropbox 4) Write the application number 5) Add the PAN card ID 6) Click on 'I am not a...

Mankind Pharma IPO: The initial public offering ((IPO) of Mankind Pharma Ltd opened for subscription on 25th April 2023 and it will remain open for bidding till 27th April 2023. This means, today is the last day to apply for the public issue worth ₹4,326.36 crore. As per the Mankind Pharma IPO subscription status, by 11:09 AM on day three of bidding, the public issue got fully6 subscribed. According to market observers, shares of Mankind Pharma is available at a premium of ₹70 in grey market today. 2] Mankind Pharma IPO subscription status: By 03:05 AM on day 3 of bidding, the public issue has been subscribed 10.45 times whereas its retail portion has been subscribed 0.69 times. The public offer has been fully subscribed in NII and QIB category. In NII category, the IPO has been subscribed 3.18 times whereas in QIB segment, it has been subscribed 34.18 times of its original offer. 3] Mankind Pharma IPO date: The public issue opened for subscription on 25th April 2023 and it will remain open for bidding till 27th April 2023. 4] Mankind Pharma IPO price band: Manforce and Prega News maker company has fixed price band of its public offer at ₹1026 to ₹1080 apiece. 5] Mankind Pharma IPO lot size: A bidder will be able to apply in lots and one lot of the IPO will comprise 13 shares. 6] Mankind Pharma IPO investment limit: As one lot will have 13 company shares, minimum amount required for a retail investor to apply for Mankind Pharma IPO is ₹14,040 ( ₹1080 x 13). 7] Mankind Phar...

Mankind Pharma IPO: The initial public offering (IPO) of Mankind Pharma Ltd is going to hit stock market today. As epr the information available on BSE website, Mankind Pharma share price is going to list on both NSE and BSE on 9th May 2023 i.e. today. Thus, ₹120 per equity share in grey market today while stock market experts are also expecting positiver debut of Mankind Pharma shares. They said that an allottee may have a listing premium to the tune of 10-12 per cent and Mankind Pharma IPO listing price could be around ₹1300 apiece, provided bull trend continues on Dalal Street today. Mankind Pharma share price debut: What experts feel? Speaking on Mankind Pharma share price debut, Prashanth Tapse, Senior Vice President at Mehta Equities said, "Expecting a decent listing gains of around 7-10 per cent on the issue price considering healthy market mood and a strong subscription response from the investors, led by the institutions while the offer also witnessed muted response from the retailers due to concern on 100 per cent OFS." On expected Mankind Pharma IPO listing price, Ravi Singhal, CEO at GCL Broking said, "Much will depend upon the kind of opening ₹1,300 apiece levels whereas in bear case, we may see Mankind Pharma ₹1,100 apiece levels." Mankind Pharma IPO GMP today As mentioned above, market observers have informed that Mankind Pharma IPO GMP (grey market premium) today is ₹120 per equity share, which is ₹17 higher from its yesterday's GMP of ₹103. Observers went ...

IPO Size: Rs. 4,326 cr • Entirely offer for sale (OFS) – comprising 1/4 th by promoters (79% to 76%), 3/4 th by 2 PE investors Capital International and ChrysCapital (21% to drop to 13%) Price band: Rs. 1,026-1,080 per share M cap: Rs. 43,264 cr, implying 10% dilution IPO Date: Tue 25 th April to Thu 27 th April 2023, Listing Tue 9 th May 2023 Grey Market Premium (GMP): We are strongly against ‘ grey market premium’ as it is an unofficial figure, against SEBI guidelines. India’s Fourth Largest Pharma Company Mankind is an India focused branded generics pharmaceutical company, clocking 10% of Rs. 8,500 cr annual revenue from over-the-counter (OTC) healthcare products like contraceptives, pregnancy kits, antacids etc and 90% from higher-margin chronic and acute pharma segments, in the ratio of 1:2. With a deep reach of 15,000+ field managers and medical representatives, Mankind enjoys 4.4% market share in Rs. 1.9 lakh cr Indian Pharmaceutical Market (IPM) and 5.7% volume market share as its drugs are competitively priced. As 98% revenue is from India, Mankind is insulated from USFDA risks plaguing some of its peers. Multiple Growth Opportunities • Mankind is only the 2 nd company in the world (after Abbott) to have developed a complex synthetic hormonal API dydrogesterone in-house (marketed as Dydroboon) , revenue from which increased from Rs. 85 cr in FY21 to Rs. 205 cr in TTM Dec 22, as market grows at 35% CAGR. A new manufacturing facility for Dydroboon export is under co...

Mankind Pharma closed its maiden public issue on a strong note, getting subscribed over 15 times. Now all eyes will be on its share allotment which will be announced next week on May 3. The pharmaceutical company has received a robust response to its initial public offering from qualified institutional investors, who have bid 49.16 times the allotted quota, while high net-worth individuals have bought shares 3.8 times the reserved portion. However, the response from retail investors remained tepid, with only 92 percent of reserved shares subscribed. As a result, the offer has received bids for 42.95 crore equity shares subscribing 15.32 times during April 25-27. The company also received a good response in the anchor round with 16 MF schemes and names like CPPIB, Abu Dhabi Investment Authority, Goldman Sachs, Fidelity, Blackrock, GIS and Nomura participating. The Rs 4,326-crore public issue was entirely an offer for sale by promoters and investors. Hence all the money will go to the selling shareholders, and the company will not receive funds from this offer. The price band for the offer was Rs 1,026-1,080 per share and the final offer price is expected to be at the upper end of the price band. Investors in the Mankind Pharma IPO can check their share allotment status either on the BSE website or the portal of the IPO registrar, by following a few easy steps. In case of IPO registrar website, a) Select IPO "Mankind Pharma Limited" b) Select and accordingly enter either "Ap...